7.60
Maravai Lifesciences Holdings Inc (MRVI) 最新ニュース
Maravai LifeSciences Holdings, Inc. (MRVI) Stock Price, News, Quote & History - Yahoo! Finance Canada
MRVI: Strong 1H 2026 growth and cost reductions drive a profitable, diversified life sciences platform - TradingView
Is Maravai LifeSciences Holdings (MRVI) Cheap If Cash Flow Recovers? - Yahoo Finance
Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In? - Yahoo Finance
Maravai LifeSciences stock gains 3.74 percent as market value reaches USD 326.82 million - ad-hoc-news.de
Maravai LifeSciences stock falls after recent slide, investors eye latest results - ad-hoc-news.de
Maravai LifeSciences Holdings (MRVI): Investor Outlook Reveals 2% Potential Upside Amidst Industry Growth - DirectorsTalk Interviews
Maravai LifeSciences Holdings, Inc.Class A common stock (NQ: MRVI - The Chronicle-Journal
Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) Stock Price, News & Analysis - kalkine.com.au
Maravai Lifesciences CEO Brust Bernd Forfeits 29,250 Shares at $7.32 Each (NASDAQ: MRVI) - Kalkine Media
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com South Africa
MRVI Maintained by UBS -- Price Target Raised to $8.00 - GuruFocus
UBS Adjusts Maravai Lifesciences Price Target to $8 From $2.50, Maintains Neutral Rating - Yahoo Finance
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel (MRVI) - Seeking Alpha
Maravai (NASDAQ: MRVI) CFO now holds 423K shares after tax withholding - Stock Titan
Maravai (MRVI) Technicals: Ends Up by 4.22% at $8.64 in Latest Trading - vinanet.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Why Maravai LifeSciences Holdings (MRVI) Stock Climbed After Its Latest Update - Sahm
Maravai Lifesciences stock reaches 52-week high of 8.15 USD By Investing.com - Investing.com Nigeria
Maravai Lifesciences stock reaches 52-week high of 8.15 USD - investing.com
Maravai (MRVI) Earnings Reading: EPS Prints Above Forecast in the Latest Reading; Closing Move: The Market Price Advances 25.78% in Latest TradingPost-Announcement Reaction - vinanet.vn
Maravai Lifesciences Up Over 30%, on Pace for Largest Percent Increase in Over a Year -- Data Talk - Bitget
MRVI Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost DisciplineNew Analyst Coverage - vinanet.vn
Maravai Lifesciences Earnings Call Highlights Margin Rebound - TipRanks
MRVI Q2 2026 Earnings: Loss Narrows Sharply as EPS Beats Estimates by 54.65%Post-Announcement Reaction - vinanet.vn
Maravai LifeSciences (MRVI) Slides 1.38% to $5.70 as Key Support Level Comes into FocusALMA Signal - vinanet.vn
Wall Street Zen Upgrades Maravai LifeSciences (NASDAQ:MRVI) to Buy - MarketBeat
Maravai (MRVI) Q2 2026 Earnings Call Transcript - AOL.com
Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake - Stock Titan
Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Maravai Q2 2026 slides: margin expansion drives EBITDA guidance raise By Investing.com - Investing.com Nigeria
Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss Narrows - Quiver Quantitative
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - Moomoo
Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history - Yahoo Finance Singapore
MRVI Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $6.50 - GuruFocus
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap DownHere's What Happened - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - MarketBeat
Maravai LifeSciences posts investor presentation on mRNA, gene editing, cell and gene therapy tools platform - Bitget
Earnings call transcript: Maravai LifeSciences beats Q2 2026 estimates, shares fall - Investing.com South Africa
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with Biotech Innovation - DirectorsTalk Interviews
MRVI Looks 63.2% Overvalued on GF Value™ - GuruFocus
Is Maravai LifeSciences (MRVI) Overvalued After Q2 Earnings Miss? GF Score: 61/100 - GuruFocus
Maravai LifeSciences (MRVI) Plunges 9.92% as Shares Test Critical $5.35 Support ZoneFear Greed Extreme - dars.gov.et
Maravai LifeSciences Q2 Earnings Call Highlights - TradingView
Maravai LifeSciences Holdings Inc (MRVI) (Q2 2026) Earnings Call - GuruFocus
Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Inv - The National Law Review
Maravai LifeSciences Holdings, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-08-06 - Seeking Alpha
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Maravai LifeSciences Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Maravai LifeSciences Holdings Inc Earnings Call Transcript - GuruFocus
MRVI: Q2 revenue up 9% to $51.4M; EBITDA guidance raised on margin expansion confidence - TradingView
MRVI: Revenue and margins rose sharply in H1 2026, with net loss narrowing and debt refinanced - TradingView
Maravai LifeSciences Reports Second Quarter 2026 Financial Results - Yahoo Finance
Maravai Lifesciences in focus: Can Q1 momentum hold in earnings? - Investing.com
Maravai Lifesciences in focus: Can Q1 momentum hold in earnings? By Investing.com - Investing.com Nigeria
大文字化:
|
ボリューム (24 時間):